Key facts
- It has raised $100K; the latest was Early Stage VC in Apr 2025.
- Notable investors include Alumni Ventures, Climate Capital, E14 Fund, The Engine, Activate Global — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Anthology
- ·The full record, as it builds
Funding rounds
No funding rounds for Anthology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anthology
Developer of a genome evolution technology designed to scale and digitalize biomanufacturing. The company's technology integrates advanced technologies and innovation in biomanufacturing processes and accelerates the speed of genetic mutations and selection in organisms that make carbon-neutral and carbon-negative bioproduction possible, enabling researchers in the life sciences sector to streamline workflows and achieve greater efficiency in genome development.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 8
- Website
- anthology.bio/
- Ownership
- Privately Held (backing)
Anthology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anthology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anthology in its N-PORT filings yet. We sweep new filings monthly.